Total pineal endocrine substitution therapy (TPEST) as a new neuroendocrine palliative treatment of untreatable metastatic solid tumor patients: A phase II study

Neuroendocrinology Letters

Volumn 24, Issue 3-4, 2003, Pages 259-262

  Lissoni, Paolo ^a   Malugani, Fabio ^a   Brivio, Fernando ^a   Piazza, Alessandra ^a   Vintimilla, Carmen ^a   Giani, Luisa ^a   Tancini, Gabriele ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

Melatonin; Pineal gland; Pineal indoles; Supportive care

Indexed keywords

5 METHOXYINDOLEACETIC ACID; 5 METHOXYTRYPTAMINE; 5 METHOXYTRYPTOPHOL; INDOLE DERIVATIVE; MELATONIN; PINEAL BODY HORMONE;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; DRUG RESPONSE; ENDOCRINE FUNCTION; FEMALE; HORMONE RELEASE; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; MALE; METASTASIS; METASTASIS INHIBITION; NEUROENDOCRINE SYSTEM; PALLIATIVE THERAPY; PHASE 2 CLINICAL TRIAL; PINEAL BODY; SOLID TUMOR; TREATMENT FAILURE;

EID: 0042286457     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Lissoni P, Viviani S, Bajetta E, et al. A clinical study of the pineal gland activity in oncologic patients. Cancer 1986; 57:837-842.
2. Lissoni P. The pineal gland as a central regulator of cytokine network. Neuroendocrinol Lett 1999; 20:343-349.
3. Regelson W, Pierpaoii W. Melatonin: a rediscovered antitumor hormone ? Cancer Invest 1987; 5:379-385.
4. Brzezinski A. Melatonin in humans. N Engl J Med 1997; 336:186-195.
5. Lapin V, Frowein A. Effects of growing tumors on pineal melatonin levels in male rats. J Neural Transm 1981; 52:123-126.
6. Bartsch H, Bartsch C. Effect of melatonin on experimental tumors under different photoperiods and times of administration. J Neural Transm 1981; 52:269-279.
7. Anisimov VN, Poppvich IG, Zabezhinski MA. Melatonin and colon carcinogenesis. Carcinogenesis 1997; 18:1549-1553.
8. Vijayalaxmi C, Thomas CR, Reiter RJ, Herman TS. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 2002; 20:2575-2601.
9. Prozialeck WC, Boehme DH, Vogel WH. The fluorometric determination of 5-methoxy-tryptamine in mammalian tissues and fluids. J Neurochem 1978; 30:1471-1475.
10. Beck O, Jonsson G, Lundman A. 5-methoxyindoles in pineal gland of cow, pig, sheep and rat. P Pharmacol 1981; 318: 49-52.
11. Vigano D, Lissoni P, Rovelli F, et al. A study of light/dark rhythm of melatonin in relation to cortisol and prolactin secretion in schizophrenia. Neuroendocrinol Lett. 2001 22:137-41.
12. Iguchi H, Kato KI, Ibayashi H. Age-dependent reduction in serum melatonin concentrations in healthy human subjects. J Clin Endocrinol Metab 1982; 55:27-29.
13. Hadjiu SI, Porro RS, Lieberinan PH, Foote FW. Degeneration of the pineal gland of patients with cancer. Cancer 1972; 29:706-709.
14. Sze SF, Ng TB, Liu WK. Antiproliferative effect of pineal indoles on cultured tumor cell lines. J Pineal Res 1993; 14:27-33.
15. Conti A, Maestroni JGM. The clinical neuroimmunotherapeutic role of melatonin in oncology. J Pineal Res 1995; 19: 103-110.
16. Guerrero JM, Reiter RJ. Melatonin-immune system relationships. Curr Topics Med Chem 2002; 2:167-180.
17. Sze SF, Liu WK, Ng TB. Stimulation of murine splenocytes by melatonin and methoxytryptamine. J Neural Transm Con Sect 1993; 94:115-126.
18. Lissoni P, Fumagalli L, Paolorossi F, et al. Anticancer neuroimmunomodulation by pineal hormones other than melatonin: preliminary phase II study of the pineal indole 5-methoxytryptophol in association with low-dose IL-2 and melatonin. J Biol Regul Homeost Agents 1997; 11:119-122.
19. Lissoni P. Is there a role for melatonin in supportive care? Supp Care Cancer 2002; 10:110-116.
20. Lissoni P, Rovelli F, Frassineti A, et al. Oncostatic activity of pineal neuroendocrine treatment with the pineal indoles melatonin and 5-methoxytryptamine in untreatable metastatic cancer patients progressing on melatonin alone. Neuroendocrinol Lett. 2000; 21:319-323.
21. Lissoni P, Rovelli F, Malugani F, et al. Anti-angiogenic activity of melatonin in advanced cancer patients. Neuroendocrinol Lett. 2001; 22:45-7.
22. El-Domeiri AAH, Das Gupta TK. Reversal by melatonin of the effect of pinealectomy on tumor growth. Cancer Res 1973; 33: 2830-2833.